BowTiedBiotech 🧪🔬🧬
@BowTiedBiotech
Followers
16K
Following
15K
Media
5K
Statuses
22K
Daily Biotech Updates: Public & Private Market Updates, Company Building, Financing, Exit Strategies, & Emerging Science Trends | Current: Janitor at Biotech VC
United States
Joined November 2021
Degrader Tac-opedia . 🔘PROTAC: E3 ligase-targeted proteolysis.🔘DUBTAC: Deubiquitinase stabilization.🔘LYTAC: Lysosome-targeted degradation.🔘Trivalent PROTAC: Multivalent E3 ligase.🔘AUTAC: Autophagy-targeted degradation.🔘RIBOTAC: RNA-targeted degradation.🔘RNA-PROTAC:
4
201
902
2023 Blockbuster Drugs (sales). Source: Anis Fahandej-Sadi on the HR App!
4
78
265
FDA Development Paths. 1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly. 2️⃣ Orphan Designation: Reserved for drugs targeting rare
3
23
149
🔮Projected 2024 Drug Approvals . By MOA:.Claudin 18.2: gastric cancer.TILs: melanoma.Thb: NASH.HT2A: schizophrenia.Activin-R: PAH.HIF-PHIs: CKD.Aβ: AD.HER3 ADC: NSCLC.RAFi: glioma.Telomerase: MDS/MF.DLL3-CD3: SCLC.FIX: Hem B.FDi: PNH.C5i: PNH.KarXT: schizophrenia. Source: Chris
3
30
143
PHARMA HISTORY: Top 10 BY MARKET CAP. 2004: Pfizer “King of Lipids - Lipitor”.2005-11: JNJ “TNF Time - Remicade”.2012: Roche “HER Too - Herceptin”.2013-21: JNJ “Bloody Blockbuster - Imbruvica”.2022-23: Lilly “The Obesity Show - Mounjaro”. Source: Joana Sadowska on the HR APP
4
67
141
11 CLINICAL TRIALS THAT WILL SHAPE MEDICINE IN 2024. 🧬 Our eyes are on VERVE-101 as it will be the first gene editing POC in common disease. Will many patients choose with statin refractory hypercholesterolemia choose gene editing? Likely not in our view. BUT - this study
2
26
134
1/ 🧠💻AI in Biopharma.Case Study: Roche. We will get more into this in the coming weeks in a Sunday newsletter. Sunday's are where we discuss topics related to emerging biopharma strategy. But follow this thread for some super cool real life use cases from Roche 🧵👇
2
20
127
10 𝗙𝗶𝗿𝘀𝘁-𝗶𝗻-𝗖𝗹𝗮𝘀𝘀 Drugs on Track for FDA Approval in 2025. $IONS $SNY $RGNX $VRTX $ABBV $SWTX $ARWR $URGN $RARE. Source: Maryam Daneshpour on the HR app!
7
20
124
Approved Cell and Gene Therapies. 🔘Hematology (21).🔘Oncology (5).🔘Neurology (4).🔘Dermatology (3).🔘Immunodeficiency (1).🔘Endocrinology (1).🔘Ophthalmology (1).🔘Musculoskeletal (1).🔘Aesthetic (1). H/T: Dr Jojo on the HR app!
2
39
116
💡Exciting Emerging Science. 1. In-vivo CART / reprogramming.2. Full gene knock-in.3. Non-viral GTx.4. AID - TReg biology.5. RNA Editing .6. Epigenetic editing.7. Fibrosis .8 Tech to limit Off Target Editing.9. miRNA to modulate RNA expression.10. Nucleic acid immune modulators.
7
20
110
Synthetic Enzymes coming soon?. Below not as a therapeutic but to enhance biosynthesis - huge market opportunity…. Accelerated enzyme engineering by machine-learning guided cell-free expression. “We use these data to build augmented ridge regression ML models for predicting
2
35
106
👀in-vivo CAR-T will be in the clinic 2024. Two companies to file INDs:.👉🏼Interius BioTherapeutics .👉🏼Umoja Biopharma. 🐒Interius reported that B-cell counts were reduced by at least 75% in 15 out of 16 animals.
5
18
101
HUNTING GROUNDS FOR MEGA-BLOCKBUSTERS.TAM for Top 25 Serious Disease . T2D: $431B.Obesity: $250B.Migraine: $240B.Pain: $220B.Addiction: $147B.Heart Disease: $142B.Autism: $132B.Alzheimer's: $120B.Hypertension: $114B.COPD: $114B.CKD: $79B.Depression: $79B.Endometriosis: $78B.Heart
7
26
97
Breaking Down the Pharma Industry: Profit vs. Revenue. Below is how pharma giants stack up in terms of profit vs. revenue?. Total profit: $173.5B.Total revenue: $972.3B.Profit margin: 17.84%. Source: Reza Zahiri on the HR app!
5
20
92
Categorizing Immunotherapy. Tumour-Infiltrating Lymphocytes (TIL).T Cell Receptor-Engineered T cells (TCR-T).Chimeric Antigen Receptor T cells (CAR-T).Chimeric Antigen Receptor Natural Killer cells (CAR-NK).Chimeric Antigen Receptor Macrophages (CAR-M). Chimeric Antigen Receptor
2
17
88
Top Drug Sales (2022 vs 2023). 1. Keyruda $MRK $20.9B vs $25B.2. Humira $ABBV $21.B vs $14.4B.3. Ozempic $NVO $8.6B vs. 13.0B.4. Eliquis $BMY $PFE $11.8B vs $12.2B.5. Biktarvy $GILD $10.4B vs $11.5B.6. Dupixant $SNY $REGN $8.9B vs. $11.5B.7. Comirnaty $PFE $37.8B vs. $11.2B.8.
1
22
82
💰💊 Big Pharma has committed a staggering $5.5B to AI drug discovery partnerships in Q4-2023. Source: Hannah Finnegan
4
15
85
Average Cost to Develop a Drug remains ~$2B. (Includes cost of failure). Source: Deloitte
5
21
75
RECENT BIOTECH SHUTDOWNS.(Since May 2024). 🤚 We suspect more of this as well as a wave of consolidations as companies run out of cash & are unable to finance. 💡 It is also a tremendous opportunity for consolidation as many of these companies will have “advancable” clinical
4
15
79
ADC History: 7% Success Rate over 40 years. 349: have entered human studies.190: in active development .148: discontinued. 11: approved by FDA. 348-190=158 either approved or discontinued if remove those still progressing as TBD. 11/158 = 7% success rate. REMEMBER WHEN PAYING FOR.
Landscape of ADCs by Dr. LoRusso. 11 approved ADCs among 349 ADCs that have entered the clinic (148 discontinued). Developing ADCs for solid tumor is challenging given antigens being “tumor-associated” not “specific” and heterogeneity of cancer cells among many reasons. #ASCO24
6
10
80
in-vivo reprogramming is coming…. In vivo dendritic cell reprogramming for cancer immunotherapy.
4
13
78
Who are the largest #biotech investors and how are they doing (via AUM). 1. Baker Bros - 23B.2. Orbi - $18.3B.3. Deerfield - $15.1B.4. RA - $10.8B.5. Perceptive - $9.5B. Source: Torreya
1
20
78
1/ 📊The bar has risen for U.S. biotech, thanks to intense competition from China’s growing biotech ecosystem 🇨🇳 . What does this mean for U.S. biotechs? Adapt or get left behind. 🧵
6
13
77
Biotech Buyout Basket (BBB) #JPM25. Building on @Andre_AGTC we took his list of biotechs with high profile programs NOT presenting at JPM and overlaid alignment with pharma R&D strategy and balance sheet flexibility for deal making. The thesis is high profile biotechs not
Revised .Many reasons company not to present on JPM25 but one I like is that they might be in a confidential blackout period .If, by any remote chance, a M&A is announced on JMP25, it would be one of the below.$AXSM $ITCI $ARVN $KRYS $VRNA $PRAX $MLTX $VRDN.
6
9
77
Our list going into 2024. likely forgot a few.$biotech. CV NASH: $MDGL .CV Obesity: $GPCR $VKTX.CV HF: $CYTK.I&I FcRN: $IMVT $ARGX .I&I IL17: $MLTX .I&I Degraders: $KYMR.Rare: $BBIO .Neuro/I&I/Obesity: $BHVN .Oncology: $RVMD.RNAi: $ARWR $ALNY.
13
15
73
The only thing right about the forecast is that is it wrong!
7
8
76
1/ How does a cancer vaccine work?. Step 1: Manufacturing
1
11
70
If you are a biotech junky (like us) this is must watch TV. The @TimOpler breaking down the history AND future of healthcare. Amazing story, and super interesting data cuts. Enjoy 🎬
6
13
71
Q2 Biotech Hedge Fund performance moving in right direction after slaughter over last 3 years. Q2. BVF: 39%.Cormorant: +23%.Samsara: +21%.Logos: +17%.Deep Track: +17%.EcoR1: +13%.RA: +11%.Fairmont: +10%.Boxer: +7%.Perceptive: +6%.Avoro: +4%.Tang: +2%.Baker Bro: -6%.Orbi: -11%
Epoch 33: 1H23 #Biotech Hedge Fund Performance. ✅Macro impact on biotech 2H23?.✅What biotech hedge funds are buying?.✅What biotech hedge funds are selling?.✅Q2 and 3yr biotech HF performance. (Link to subst**ack in bio)
2
14
66
😱😱😱 Cell and gene therapy investment, once booming, is now in a slump. "Much less money is flowing into the sector as venture investors focus on technologies with less risk and easier paths to market.". This article is sure to touch a nerve! 😀.
2
17
69
Private Biotech Step-Up Medians. Seed-Series A: 1.25x (24% down rounds).Series A - Series B: 1.35x (11% down rounds).Series B - Series C: 1.13x (33% down rounds).Series C - forward: 0.86x (68% down rounds). Flat is the new up if you are lucky. just brutal out there
4
18
71
$IPSC Clears 6mon complete response.If they get to 12mon PFS cell therapy is back!. CNTY-101 is an allogeneic anti-CD19 iPSC-derived NK cell therapy. 🧬✂️ 6 Precision Gene Edits.1️⃣Avoid Tcell rejection: KO B2M.2️⃣Avoid Tcell rejection: KO MHCII.3️⃣Avoid NK Rejection: KI HLA-E
7
12
70
💰Obesity Market Peak Sales Projections. Saxenda $NVO $1.5B.Wegovy $NVO $14.5B.Mounjaro $LLY $10.7B.CagriSema $NVO $35B.Retatrutide $LLY $30.5B.Orforglipron $LLY $2.3B.Danuglipron $PFE $2.3B. Source: Barclays
🚨$60B+ Market Opportunity: #Obesity Therapeutics . Approved: Wegovy (GLP-1) Mounjaro (GLP-1/GIP). Up Next:. CagriSema $NVO.Retatrutide $LLY GCGR/GIPR/GLP-1R.Orforglipron $LLY oral GLP1.Danuglipron $PFE oral GLP1.AMG-133 $AMGN GIPR antagonist . Source: Barclays.
7
15
64
📬mRNA/LNP companies we are most excited about:. 1. Orna (Anderson).2. ReCode (Seigwart).3. Capstan (Weissman).4. Strand (Weiss, Irvine).5. Orbital Therapeutics (Chang, Weissman).6. Sanofi / Tidal Therapeutics (Irvine). Who did we miss?.
4
11
65
3️⃣2️⃣ FDA APPROVED Cell & Gene Therapies.1️⃣8️⃣ EMA APPROVED C>. ✅ Haematology: 18 (FDA), 9 (EMA).✅ Ophthalmology: 1 (FDA), 2 (EMA).✅ Neurology: 3 (FDA), 3 (EMA).✅ Gastroenterology: 0 (FDA), 1 (EMA).✅ Immunodeficiency: 1 (FDA), 1 (EMA).✅ Musculoskeletal: 1 (FDA), 1 (EMA).✅
2
15
65
JPM home stretch - hot takes 48hrs into it…. 1️⃣ SF is NOT safe.2️⃣ Waymo is cool.3️⃣ Biotechs still need capital.4️⃣ Investors still have capital to deploy.5️⃣ Many deal discussions in play (with privates).6️⃣ Many private co hypotheses to play out in clinic.7️⃣ Lots China assets -.
4
4
66
🇨🇳China's clinical speed advantage in action. 2 years is the global average to have 3 drugs in the same class on the market after FIC launch
3
10
65
THIS IS A BIG DEAL IN BEYOND GLP OBESITY WORLD $BIOA -75% 😱 . BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity. Who else works on Apelin?
8
10
66
My RFK take and why I am not worried. 1. What politicians say and what they actually do are two different things - let’s see what he does / can actually do. 2. I hear many ppl repeating things about him which I know are not his position bc I have listened to him and read his.
20
4
64
👀This one for the $PFE / $SGEN haters that say Pfizer paid too much. $50-60B in 2030 projected WW sales from 3 $SGEN ADCs. 14 ADCs in the $PFE pipeline that will add to those numbers . Source: Guggenheim
3
8
63
DOGE THIS! Pharma Revenue per Employee. Top 10 most efficient:.1️⃣ $VRTX - $1.9M.2️⃣ $GILD - $1.5M.3️⃣ $BMY - $1.5M.4️⃣ $AGN - $1.4M.5️⃣ $BIIB - $1.3M.6️⃣ $ABBV - $1.1M.7️⃣ $AMGN - $1.1M.8️⃣ $GENMAB - $1.0M.9️⃣ $REGN - $1.0M.🔟 $MRNA - $0.9M
2
10
65
Obesity update: where we stand post Cagrisema P3 readout. 1. GLP-1 / GIP / Glucagon provides best weight loss $LLY. 2. GLP-1 / GIP - data looks stronger than #1 triple G at week 12 $VKTX. 3. GLP-1 / Amylin is a close second & will have a place in the market, but not dominate as
5
13
64
👀CROs as a proxy for biotech health.$CRL -12%. “One of the drug industry's biggest service providers shared a chilling message for the industry on Wednesday: Expect early pipelines to shrink and research work to decrease as big pharma companies cut costs.”. “The Wilmington,
7
8
63
Major Blockbuster Drug LOEs. Revenues at risk:.🔘 Trikafta ( $VRTX ) $8.9B.🔘 Mounjaro ( $LLY ) $5.2B.🔘 Rinvoq ( $ABBV ) $4.0B.🔘 Prevnar family ( $PFE ) $6.4B.🔘 Skyrizi ( $ABBV ) $7.8B.🔘 Biktarvy ( $GILD ) $11.85B.🔘 Entyvio ( $TAK ) $4.0B.🔘 Tagrisso ( $AZN ) $5.8B.🔘
2
13
63
New money 💰 .$7.2B for biotech. Source: endpoints
6
17
61
@c_constan For neuro? Just hardcode ‘project failed’ and you’ll achieve 100% accuracy, 100% precision, and statistically significant results (p < 0.0001). 🤣🤣🤣.
0
1
62
☠️Q3 2023 #Biotech Hedge Fund Performance.From 13F filings. Baker Brothers: +2.25%.BVF: -0.10%.Deep Track: -0.96%.Logos: -3.02%.Boxer: -3.59% .Tang: -4.27%.Avoro: -5.72%.Opaleye: -6.99%.RA Cap: -7.08%.Cormorant: -8.65%.Fairmont: -9.83%.Orbimed: -11.43%.Perceptive: -13.57%.
2
15
61
May #Biotech Hedge Fund Performance. RA Cap +7.8% (+1.2% YTD).Casdin +4.7% (+10.7% YTD).Soleus +4.4% (+3.4% YTD) .Perceptive +2.4% (+8.4% YTD).RTW +1.8% (+6.4% YTD) .Averill +1.5% (+2.6% YTD) . XBI +3% (+5.6% YTD).
0
7
57
10 BOLD BOWTIEDBIOTECH PROJECTIONS FOR 2024. 1) Subdued Enthusiasm for Oral GLP-1: Structure Therapeutics $GPCR winds up with the only acceptable safety profile, but with a moderate 10% weight loss at 40+ weeks. The product finds a significant niche in a patient subsegment
5
6
59
Momentum Growing in Cell & Gene Therapy.3️⃣4️⃣C> FDA approvals in 2023.5️⃣ in the last 6mon. 𝐇𝐚𝐞𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 (20 products):.- 2 for the treatment of multiple myeloma.- 4 for the treatment of lymphoma.- 2 for haemophilia.- 10 for cell transplant-based therapies.- 2 recently
1
13
56
Cell Therapy Landscape: AutoImmunity. Source: Spencer Knight on the HR app!
3
10
57
Top 10 List of 2025’s Biggest Drugs .Ranked by projected worldwide sales:. 1️⃣ Keytruda $MRK: $31B (PD1 oncology).2️⃣ Ozempic $NVO: $22B (GLP1 obesity).3️⃣ Mounjaro $LLY: $20B (GLP1/GIP obesity).4️⃣ Dupixent $SNY: $17B (IL4/13 I&I).5️⃣ Skyrizi $ABBV: $14B (IL23 I&I).6️⃣ Eliquis $BMY.
3
5
61
⌛️Tic Toc - pharma needs M&A to offset the upcoming mountain of patent expirations. Source: @sleuthinsights
4
14
64
CAR-T quickly moving beyond Lupus for I&I. 🩸Lupus.💪🏼 Myasthenia gravis.🧠 Multiple Sclerosis .😯 Other
CAR-T therapy for multiple sclerosis enters US trials for first time $KYTX $BMY. 🧠 Going for immune rest in the brain.☢️ The neurotox issue will be interesting to monitor - BBB is decorated in CD19 and there are many cells all over the brain with it.
4
12
57
CANCER VACCINES: Tomorrow morning we will have a BIG write-up on a massive binary cancer vaccine readout coming up. 5:30am ET!. (l!nk to substa*ck in b!o)
5
14
59
LOE cliffs imminent - $BMY will not be the only Pharma to run into this narrative…
MS $BMY (UW) multiple new products will need to accelerate to build confidence that.the company can replace ~$30bn in LOE revenue between now and 2030. More M&A needed there $XBI.
6
18
56
ADC Innovators take note!.Want to get the attention of investors?.Let pharma work on the targeting. Next wave innovation includes:.💡 Recycling optimization to enhance tissue delivery.💡 Maximizing drug-to-antibody loading ratios.💡 Potency enhancement via multi-payload loading
3
17
54
Cell & Gene Therapy Approvals (US/EU).2009-2024. haematology: 20 (FDA), 10 (EMA).neurology: 4 (FDA), 3 (EMA).ophthalmology: 1 (FDA), 2 (EMA).oncology: 4 (FDA), 1 (EMA).gastroenterology: 1 (EMA).dermatology: 3 (FDA).immunodeficiency: 1 (FDA), 1 (EMA).musculoskeletal: 1 (FDA), 1
0
15
54
Top 10 Project Mega Blockbuster Drugs for 2024. 1️⃣ Keytuda $MRK: $27B.2️⃣ Ozempic $NVO: $16B.3️⃣ Dupi $REGN: $13.5B.4️⃣ Eliquis $BMY $PFE: $13B.5️⃣ Biktarv $GILD: $13B.6️⃣ Darzalex $JNJ: $12B.7️⃣ Opdivo $BMY: $11B.8️⃣ Comirnaty $PFE: $11B.9️⃣ Gardasil $MRK: $10B.🔟 Skyrizi $ABBV: $10B
3
23
55
📢Emerging Science I am excited about. 1. Targeted Delivery.2. Synthetic Protein Design.3. Beyond Cas9 .4. Full length Gene Knock-in .5. In-situ reprogramming.6. In-vivo CART.7. Synthetic DNA.9. Immune Barriers in Oncology.10. CART beyond Oncology. No small mol IYKYK. #biotech.
4
8
54
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023. $ABBV +189%.$BMY +175%. $JNJ +95%.$AZN +78%. $NVM +45%.$MRK +37% .$RHHBY +27%. $PFE +13%.$GSK +13%. ----- $SPY +12% -----. $SNY +3%. Source: Arjun Murthy on the HR app!
3
10
54
@BowTiedShrike @ResearchHub @BowTiedBull This is the wildest thing I have seen today! 😂. Congrats @BowTiedShrike
3
3
55
Pharma Pipelines by number of clinical programs. **if you dont know almost all of R&D spend at pharma goes toward clinical development, a very small fraction goes toward research. If I had to guess I would say 20-30% of R&D spend on average goes to the research budget. Source:
2
9
54
Jefferies: Most likely #Biotech M&A 2023. Nice visual on potential non-risk adjusted revenue value of each - the 🔑 factor as pharma is hunting for revenues. $ALNY $ARGX $KRTX $MDGL $NTLA $RDRX $APLS $ITCI $CYTK $ASND $VTYX $AXSM $PCVX $BMRN $FGEN
1
8
52
1/ Autoimmune: BCMAxCD19 CAR-T + IL15 sushi armor🍣. This is an amazing paper from China🇨🇳, so much to unpack we will do so as thread
2
10
53
Which Pharma Produces The MOST BLOCKBUSTERS. 1️⃣ $LLY 13 total; 5 acquired.2️⃣ $AZN 13 total; 8 acquired.3️⃣ $JNJ 10 total; 3 acquired.4️⃣ $RHHBY 10 total; 5 acquired.5️⃣ $BMY 10 total; 8 acquired.6️⃣ $GILD 9 total; 2 acquired.7️⃣ $GSK 9 total; 4 acquired.8️⃣ $NVS 8 total;4 acquired.9️⃣
Epoch 41: Building Billion-Dollar Drugs. 👉Biggest projected blockbusters .👉Building via indication stacking .👉TA blockbuster prevalence.👉Average time it blockbuster .👉Build vs Buy?.👉Which pharma does blockbusters best?. (l!nk to substa**ck in b!o)
3
12
54
New C> Approved in 2024. They are not all for small rare disease. Two in particular caught my attention:. $IOVA TIL in melanoma was super impressive.$ADAP fist TCR therapy - super cool. Source: Dr JoJo on the HR app
4
17
53
(1/5) Looking to start a #biotech ? Here are the most active investors by stage - Seed, Series A, Series B. With our commentary of course! 🧵👇
2
12
50
☠️Q4 2023 #Biotech Hedge Fund Performance From 13F filings . Samsara: +53%.Orbimed: +40.7%.Perceptive: +40.3%.Logos: +38.6%.Cormorant: +29.7%.Fairmont: +29.3%. ------ XBI: +28.5% -------. RA Cap: +27.6%.EcoR1: +23%.Boxer: +22.4%.Tang: +14.9% .Avoro: +13.5% .Baker Brothers: +11.2%
4
9
52
Hi Haters! $PFE #1 pharma in revenue and by absolute sales growth in Q3 driven by paxlovid, which rose from almost nothing in Q3 2023 (~$200M) to ~$2.7B last quarter. Other notable increases were from Eliquis (up ~$100M), Vyndaqel (up ~$550M), and Xtandi (up ~$120M) . Source:
5
8
50
CAR T vs TCR Approaches. (1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, specificity, and efficacy of CAR therapies. (2) Engineered
1
8
52
Immune Reset - great slide from $CABA. It is **NOT just about depleting B-Cells. it is **ALSO about naive B-Cell recovery. Demonstrating immune reset is crucial because we currently lack a preclinical biomarker to predict efficacy. The emerging 'immune reset' hypothesis
4
4
52
ADC LANDSCAPE . Lots of players. if interested to differentiate explore the following 👇. 💡🥼Novel Approaches:. ✅ Novel Payloads.✅ Dual/Multi-Payload ADCs.✅ Novel ADC Formats.✅ Tumor Microenvironment Targeting.✅ Alternative Linkers.✅ Combos.✅ Tumor-Specific Antigen
0
13
52
Just when you thought the GLP-1 space was over-crowded….here comes China! 🇨🇳 . 🏅 FIRST Biosimilar NDA already filed!. Source: Cantor
1
10
47
🏆Top 2023 Biotech M&A. Source: joanna-sadowska on the HR app
1
11
48
❓Did you know? . The chance of a drug making it through clinical trials (Ph1 -> Approval) has jumped from 5.8% in 2022 to 10.8% in 2023. While not at historic highs, it's a significant improvement. More on this coming shortly in Sunday's newsletter which will focus on clinical
3
12
51
Top 10 most anticipated drug launches of 2024. 1. KarXT: Schiz $KRTX / $BMY $2.8B.2. Donanemab: AD $LLY $2.2B.3. Resmetiron: NASH $MDGL $2.1B.4. Sotatercept: PAH $MRK $2B.5. Dato-DXd: ADC lung & bc $DSNKY 1.8B.6. Acoramidis: ATTR $BBIO $1B.7. mRNA-1345: RSV Vx $MRNA $0.9B.8.
0
18
49
AutoImmune Cell Therapy - what is it worth?: all eyes on the $ARTV IPO today. Nothing like a little old fashioned price discovery to keep you entertained on a Friday. 🔘Kyverna Therapeutics: Their early clinical findings in multiple sclerosis (currently Phase 2) have shown
3
17
50
Pharma Obesity, Diabetes and Endocrinology Revenue > $70Bn Last Year. Source: Stifel / PharmaSights
0
13
46
I have an explanation for this. Pharma is under such pressure to deliver revenues today to replace LOEs most of the R&D budget is going toward later stage studies vs. the early stage portfolio. One extreme position that has been debated has been that pharma should not be.
Very striking how “flat” (Ph1 = Ph2 = Ph3) all these pipelines are considering the inevitable attrition rates. Shows just how dependent pharma has become on clinical-stage acquisitions.
7
5
49
The stage is set for biotech turnaround. just need the macro to support a line of sight to realized value creation from new investments. MUCHO dry powder waiting to be deployed. #biotech
3
5
46
Cell Therapy Oncology Landscape. 👉 T Cells.👉 NK Cells.👉 Other. Source: Spencer Knight on the HR App!
2
8
48
The top 10 drugs by worldwide sales in 2023. 1. Keytruda $MRK - $25B.2. Humira $ABBV - $14.4B.3. Ozempic $NOVO - $14B.4. Eliquis $BMY $PFE - $12.9B.5. Biktarvy $GILD - $11.8B.6. Dupixent $RGEN $SNY - $11.6B.7. Comirnaty $PFE $BNTX - $11.2B.8. Stelara $JNJ - $10.9B.9. Opdivo $BMY.
5
21
48
👊PHARMA INDUSTRY POWER RANKINGS. 👍🏼👍🏼👍🏼EXCELLENT. 1️⃣Johnson & Johnson ($JNJ). Strength: Strong scale advantage and a significant number of blockbuster drugs. Weakness: No major weaknesses noted; however, it lacks diversification in other concentration areas like therapeutic
1
15
47
Strategies for Targeting Tumors. 🔘 Reducing Survival.🔘 Suppressing Recruitment.🔘 Inhibiting Tumor-Promoting Function.🔘 Removing the Block (Checkpts).🔘 Inducing Repolarization.🔘 Modifying Effector Cells.
0
8
46
-51% $SGMO. This is a true proxy for the market value of gene therapy at this time……geeez. We have a near approved product with positive Ph3 data - 100s of Ms invested, and you have a big pharma saying nah you can have that, we rather not pay the milestone. Would love to see
7
5
45